Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

Performance from Laser Focused Leo has been missing

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
zandant Member Profile
Member Level 
Followed By 36
Posts 15,223
Boards Moderated 1
Alias Born 09/04/00
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/9/2021 1:45:15 PM
IQST Has Catalysts On Deck That Expose A Valuation Disconnect of Roughly 100% - Here's Why That Gap Should Close InvestorsHub NewsWire - 11/5/2021 10:20:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/14/2021 5:01:12 PM
CEO Presenting on the Emerging Growth Conference on October 13 Register Now InvestorsHub NewsWire - 10/11/2021 7:00:00 AM
CEO's Presenting on the Emerging Growth Conference 17 TODAY.  Register Now InvestorsHub NewsWire - 9/29/2021 8:00:00 AM
CLS Holdings, (OTCQB: CLSH) New Joint Venture $19 million Sales 61% Growth InvestorsHub NewsWire - 9/28/2021 7:24:31 AM
Nightfood, Inc. (OTCQB: NGTF) Significant Retail Expansion InvestorsHub NewsWire - 7/21/2021 6:47:54 AM
Innovation Pharma selected for a presentation on experimental COVID-19 therapy Seeking Alpha - 6/18/2021 10:31:54 AM
The Emerging Growth Conference is Today.  Register Now. InvestorsHub NewsWire - 6/9/2021 7:00:00 AM
Patient enrollment reaches 90 percent in Innovation Pharmaceuticals' mid-stage COVID-19 trial Seeking Alpha - 5/27/2021 10:29:46 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2021 8:01:45 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 5/3/2021 12:54:36 PM
Innovation gives update on mid-stage Brilacidin COVID-19 trial Seeking Alpha - 4/5/2021 8:03:34 AM
CLS Holdings, (OTCQB: CLSH) $1.49 million Net Revenue for Feb Highest in Company History InvestorsHub NewsWire - 3/9/2021 6:37:33 AM
Innovation updates on mid-stage Brilacidin COVID-19 trial Seeking Alpha - 3/5/2021 1:07:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/22/2021 11:20:39 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 2/17/2021 8:01:12 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/11/2021 4:47:49 PM
CLS Holdings, (OTCQB: CLSH) Record January NET Revenue of $1.48 Million Beating Target InvestorsHub NewsWire - 2/9/2021 6:48:48 AM
CLS Holdings, (OTCQB: CLSH) $17 million Sales, 60% Growth & 5 New Products InvestorsHub NewsWire - 2/2/2021 6:52:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/15/2021 12:36:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/22/2020 9:01:10 AM
Biotech Companies; Recent Milestones and Potential Upside InvestorsHub NewsWire - 12/22/2020 8:05:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/10/2020 6:03:50 AM
zandant Member Level  Friday, 10/15/21 07:57:40 PM
Re: sox040713 post# 378882
Post # of 385303 
Performance from Laser Focused Leo has been missing for years. The Compensation Committee and Board of Directors are really the One Man Band voting to compensate himself and his 3 pals if these vague objectives are met:

["The employment agreement continues Mr. Ehrlich’s current base salary of $475,000 per year and provides for (i) performance share awards under the Company’s 2016 Equity Incentive Plan, as amended (the “Plan”) with a maximum value of up to $35.0 million, contingent upon the achievement of certain market capitalization, licensing revenue and clinical trial performance goals, and (ii) cash awards with a maximum value of up to $14.0 million, contingent upon the achievement of certain market capitalization and licensing revenue goals."]

What are the "certain market capitalization, licensing revenue and clinical trial performance goals" that need to be achieved for the $35 million in share awards and the $14 million cash for the achievement of "certain market capitalization and licensing revenue goals."? Knowing how Ehrlich operates, the threshold can be extremely low.

And the 225 million shares of common stock. Are those new shares being issued or if not, where are they coming from? Are those shares in addition to the 600 million already authorized?

["Amendments to the 2016 Equity Incentive Plan — The Compensation Committee approved, and the Board of Directors ratified, amendments to the Plan to increase the number of shares of common stock available for issuance thereunder to 225 million shares, among other amendments. The foregoing description of the amendments does not purport to be complete and is qualified in its entirety by the text of the amendments, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference."]

Finally, with the underserved stock option awards, is there a predetermined price to buy the shares and if so, what is that price, and is there an expiration date?

["Annual Stock Option Awards — The Compensation Committee approved stock option awards under the Plan relating to one million shares of common stock to each independent director and 500,000 shares of common stock to each of the non-independent director and the Company's Senior Vice President, Clinical Sciences and Portfolio Management.'}

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences